|
Nicholas Bodor |
|
Design of drugs with improved therapeutic index based on retrometabolic concepts, design of soft drugs and of new chemical and physical delivery systems, computer-assisted drug design, drug transport and metabolism, and theoretical mechanistic and organic chemistry. Ongoing research is performed in all of the areas mentioned.
Consulting - Technical Expertise
|
Veronika
Butterweck |
 |
Research Interests
Research program focuses on the study of herbal medicines with CNS activity. Specific areas of focus include the investigation of plants with antidepressant or anxiolytic activity, phytomedicines for the treatment of restlessness and sleep disturbances and herbal remedies for the prevention of alcohol dependency.
|
Hartmut Derendorf |
|
Correlation of pharmacokinetic and pharmacodynamic behavior of drugs (corticosteroids, analgesics, antibiotics); analysis of drugs and metabolites in biological fluids by HPLC; pharmacodynamic evaluations by pharmaco-electroencephalography (EEG); tissue pharmacokinetics using microdialysis.
Home Page
Publication List
Consulting - Technical
Expertise
Search
PubMed for Publications
Ronald Evens,PharmD |
 |
Research Interest:
Ron Evens is President of MAPS 4 Biotec, Inc. consulting to the biotechnology industiy for strategy, planning, organization, staffing, & operations of medical affairs groups. Dr. Evens is clinical professor at University of Florida, College of Pharmacy, for pharmaceutical industry & biotechnology. Ron serves on two Boards of Directors; UF Biotechnology Development Institute and American Society of Health-Systems Pharmacists, Research & Education Foundation; & three Dean’s Advisory Boards for Colleges of Pharmacy at Florida, Kentucky, & Midwestern. Invited presentations (national and statewide) exceed 150. Publications exceed 100, including 10 book chapters. Previously at Amgen, he created and was Senior Director and Head of Professional Services Department, which was responsible for information, research, and communications for marketed products. Also, he created and was Head of PenApproval Research. Prior to Amgen, Dr. Evens was Associate Director, Clinical Research & Medical Services, at Bristol-Myers Co.; Associate Professor & Chairman of Department of Pharmacy Practice, University of Tennessee, and Associate Professor & Director of Drug Information Center, University of Texas at Austin., Dr. Evens received a B.S. in Pharmacy at University of Buffalo, N.Y. Graduate work was at University of Kentucky for Pharm. D. & residency. Fellowship was awarded with American College of Clinical Pharmacy.
|
Guenther
Hochhaus |
|
Dr. Hochhaus' research includes the development of novel analytical techniques for the measurement of drugs in biological fluids by chromatographic and immunological techniques; the metabolism, pharmacokinetic and pharmacodynamic properties of opioid peptides, pharmacokinetic/dynamic (PK/PD) behavior of anti-asthmatic drugs and their relevance for the formulation of targeted pulmonary delivery systems.
Undergraduate class PHA 5127 Basic Principles of Dose Optimization
Consulting - Technical Expertise
|
Jeffrey Hughes |
|
Research in Dr. Hughes' laboratory concentrates on understanding the physico-chemical properties of macromolecules, the biophysical factors involved in biomembrane fusion and how liposomes, and other biomolecules can be used in the delivery of drugs and other pharmaceutical applications. His group has focused on the design and synthesis of drug delivery systems which takes advantages of naturally occurring transport phenomena. This work has led to the class of compounds known as biodegradable pH-sensitive surfactants; they undergo a pH dependent ionization leading to increased surface activity and membrane fusion. Dr. Hughes' laboratory devises synthetic systems to deliver macromolecules including oligonucleotides and plasmid DNA across membranes, and employs such systems to target macromolecules to cells and organs with particular interest in the brain and lung. The other research interest of Dr. Hughes, is the pre-formulation studies with polymers of nucleic acids. The research group is currently identifying pharmaceutical relevant factors which influence the solution and solid-phase stability of macromolecules such as oligonucleotides and plasmid DNA. Dr. Hughes is on the editorial board of J Drug Targeting and Drug and the Pharmaceutical Sciences (published by Marcel Dekker).
Check out my laboratory's homepage which is under construction.
Consulting - Technical Expertise
|
Cary Mobley, RPh,PhD
Clinical Associate Professor University of Florida Email:mobley@cop.ufl.edu Tel: (352)273-6282 Fax: (352)273-7854 |
 |
Research Interests:
Use of liposomes for pulmonary delivery and as oral vaccine adjuvants. Conceptual
integration of the pharmacy curriculum.
Anthony Palmieri III, PhD, RPh |
|
Research Interests
Anthony Palmieri holds a BS and MS in pharmacy from the University of Rhode Island and the Ph.D. from the University of Georgia. Prior to his present position in the Department of Pharmaceutics, he was Assistant Director of Technology Licensing at UF. Prior to that, he was at The Upjohn Company for sixteen years. Palmieri was professor of pharmacy at the University of Wyoming. He is the author of numerous scientific, academic, and historical papers. He served as the Laboratory Editor for the third edition of the Handbook of Pharmaceutical Excipients. Palmieri is very active on the national level of Kappa Psi Pharmaceutical Fraternity and is past national president. Palmieri is past chairman of the Academy of Pharmaceutical Research and Science as well as Chair of the basic Sciences Section of APRS. He is a fellow of APhA-APRS and has authored chapters on dissolution, microencapsulation, pharmaceutical excipients and history of pharmacy. Palmieri is a recognized expert on drug delivery, dissolution and intellectual property. He is currently Chair of the United States Adopted Names Council. He was the editor as well as an author of “Dissolution Theory, Methodology and Testing”.
|
Michael
A. Schwartz, PhD, |
|
|
Sihong Song, PhD, |
 |
Research Interests
Dr. Song's interests are in 1) improvement of safety and efficiency of rAAV vector by understanding molecular mechanisms of persistence and integration of the AAV genome in mammalian cells and 2) the use of recombinant Adeno-Associated Virus (rAAV) vectors mediated gene transfer to develop gene therapy approaches for common diseases such as diabetes and arthritis.
Return to Pharmaceutics HomePage
Last modified April 18, 2008
